非银金融 2026 年 02 月 01 日 投资评级：看好（维持） 行业走势图 数据来源：聚源 -10% 0% 10% 19% 29% 2025-02 2025-06 2025-10 非银金融 沪深300 相关研究报告 《偏股基金新发同比明显增长，公募 强化基准约束—行业周报》-2026.1.25 《逆周期调节呵护"慢牛"，券商和 保险业务开门红 — 行 业 周 报 》 -2026.1.18 《衍生品监管透明化，规模限制有望 放松利好头部券商—衍生品监管政策 点评》-2026.1.18 （1）本周日均股基成交额 3.71 万亿，环比+7.7%，2026 年 1 月市场日均股基成 交额 3.65 万亿，同比+157%；2026 年 1 月新成立股票和混合类基金份额 812 亿， 环比+66%，同比+187%。开年首月基金新发和交易量均显著扩张。（2）1 月 30 日证监会召开资本市场"十五五"规划上市公司座谈会，证监会主席吴清强调：全 力巩固资本市场稳中向好势头，聚焦持续深化资本市场投融资综合改革、提高制 度包容性适应性，抓紧推出深化创业板改革，提高再融资制度便利性、灵活性和 吸引力。（3）截至 1 月末，已披 ...

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Insights - The humanoid robot sector has experienced significant fluctuations, with a notable decline of 8.73% in the core company index, underperforming the CSI 300 index which saw a slight increase of 0.08% [11][12] - Tesla's CEO Elon Musk emphasized the acceleration of humanoid robot production, aiming for a capacity of 1 million units at the Fremont factory by 2026, marking a pivotal shift towards mass production [12][18] - The report highlights the potential of the humanoid robot industry to enter a "golden decade" as production ramps up from 2025 to 2026, transitioning from initial development to mass deployment [12][18] Summary by Sections Section 1: Market Overview - The humanoid robot sector has faced a significant downturn, with individual stocks showing varied performance, including notable declines for companies like Longsheng Technology and Weichuang Electric [11][12] - The overall market sentiment is affected by short-term catalysts such as factory audits and Tesla's earnings call, alongside seasonal shifts in investment preferences as the Chinese New Year approaches [12] Section 2: Space Mining and Robotics - China is advancing its space resource development strategy, focusing on key technologies for asteroid resource exploration and intelligent autonomous mining [18][19] - The report identifies the challenges of space mining, including microgravity and high radiation environments, which necessitate advanced robotic technologies [20][26] - Humanoid robots and other multifunctional robots are expected to play a crucial role in space mining operations, capable of performing various tasks in extreme conditions [20][35] Section 3: Beneficiary Segments - The commercial space sector is poised for growth, driven by policy support and increasing demand for satellite launches and networks [41] - Key beneficiaries in the humanoid robot and commercial space sectors include companies involved in core components, structural parts, and specialized robotics [42] - The report lists specific companies that are expected to benefit from advancements in humanoid robotics and space mining technologies, including Blue Sky Technology and Junsheng Electronics [42]

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Insights - The report highlights the emergence of HBN, a leading domestic skincare brand, which has submitted its prospectus to the Hong Kong Stock Exchange, indicating strong growth potential in the efficacy skincare market [3][24] - The report emphasizes the importance of emotional consumption themes and recommends high-quality companies in high-growth sectors, including gold and jewelry, offline retail, cosmetics, and medical aesthetics [6][49] Summary by Sections Retail and Social Services Market Review - For the week of January 26 to January 30, the retail and social services indices closed at 2435.34 points and 9283.84 points, respectively, with declines of 4.18% and 3.45% [5][14] - The jewelry sector showed the highest growth, with a weekly increase of 7.07% and a year-to-date increase of 19.39% [15][18] Industry Dynamics: HBN and Efficacy Skincare - HBN, established in 2019, is the largest domestic skincare brand in the efficacy segment, focusing on visible results and innovative product strategies [24][25] - The brand's core products, including the "A Retinol" series, have achieved significant sales milestones, with a strong emphasis on scientific validation and consumer trust [29][33] Investment Recommendations - Investment focus areas include: - Gold and jewelry brands with differentiated product offerings, recommending companies like Laopuhuang and Chaohongji [6][49] - Offline retail companies adapting to market changes, with recommendations for Yonghui Supermarket and Aiyingshi [6][49] - Domestic cosmetics brands that emphasize emotional value and safety, recommending brands like Maogeping and Proya [6][50] - Medical aesthetics firms with unique product lines, recommending Meilitiantian Medical Health and Aimeike [6][51]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company is expected to achieve a net profit attributable to shareholders of 1.67 to 1.85 billion yuan for 2025, representing a year-on-year increase of 54% to 71%. The non-recurring net profit is projected to be 1.62 to 1.79 billion yuan, also showing a year-on-year increase of 53% to 69%. For Q4 2025, the net profit is expected to be between -117 million to 63 million yuan, reflecting a year-on-year decline of 202% to 45% due to increased income tax and exchange losses. The profit forecast for 2025-2027 has been adjusted downwards, with expected net profits of 1.759 billion, 2.316 billion, and 2.954 billion yuan respectively, corresponding to EPS of 24.42, 32.15, and 41.00 yuan. The current stock price corresponds to P/E ratios of 21.2, 16.1, and 12.6 times for the respective years. The company is expected to maintain double-digit growth in its two-wheeler segment and stable profitability due to increased APP profits and ongoing channel optimization [5][7]. Financial Summary - The company’s revenue is projected to grow significantly, with expected revenues of 21.403 billion yuan in 2025, 29.132 billion yuan in 2026, and 37.117 billion yuan in 2027, reflecting year-on-year growth rates of 50.8%, 36.1%, and 27.4% respectively. The gross margin is expected to improve to 30.3% in 2025 and further to 31.4% in 2026. The net profit margin is projected to be 8.2% in 2025 and 7.9% in 2026. The return on equity (ROE) is expected to reach 22.1% in 2025 and 23.5% in 2026 [8][10]. Product Performance - In Q4 2025, the two-wheeler segment is expected to focus on inventory clearance, with an estimated shipment of 4.1 million units for the year and 200,000 to 300,000 units for Q4, showing a decline due to policy changes. However, the average selling price is expected to increase. The all-terrain vehicle segment is anticipated to continue its growth in non-US regions, while the lawn mower segment is expected to exceed expectations due to low inventory levels [6][7]. Growth Outlook - For 2026, the two-wheeler segment is expected to outperform industry growth, with a target of 30% volume increase driven by electric motorcycles and low inventory. The lawn mower segment is projected to double its revenue, supported by the release of nine new SKUs and channel deepening. The E-Bike segment is also expected to show strong growth potential following positive feedback from product launches [7][8].

Market Overview - The market is currently in a consolidation phase, with significant fluctuations in sectors and individual stocks, such as the liquor sector experiencing a sharp rise mid-week and the metals sector facing a substantial pullback on the last trading day, causing market panic[1] - The frequent and extreme rotation in the market increases the risk of chasing trends, suggesting that maintaining a mid-term position may be wiser[1] Investment Strategy - The report emphasizes the importance of "buying new, not old; buying big, not small" as a strategy for selecting strong themes in investment[1][2] - The current market environment is characterized by low relative gains, good safety margins, and high certainty in main categories, making it a favorable time to focus on thematic investment opportunities[1] Thematic Investment Insights - Historical data indicates that thematic investments thrive during periods of weak fundamentals and ample liquidity, with active themes often emerging when industrial profits and macroeconomic indicators are low[1][15] - The report identifies key themes for 2026, including AI, humanoid robots, and commercial aerospace, which are expected to gain traction due to technological breakthroughs and supportive policies[1][14] Mid-Cap Performance - The CSI 500 index has shown relative strength this year, attributed to precise industry allocation matching the recovery cycle, market capitalization fitting institutional needs, and liquidity supporting large capital participation[2][26] - As of January 29, 2026, the average market capitalization of the CSI 500 is 39.481 billion yuan, positioning it uniquely between large-cap and small-cap stocks, providing both a buffer and an accelerator during market adjustments[2][31] Sector Analysis - The CSI 500's sector distribution is dominated by hardware (12.07%), non-ferrous metals (9.51%), and chemicals (7.67%), contrasting with the CSI 300's focus on finance and consumer sectors, highlighting a "manufacturing + technology" growth profile[2][35] - The report suggests that the cyclical recovery in manufacturing, indicated by a PMI of 50.18%, and supportive monetary policies will benefit mid-cap growth stocks within the CSI 500[2][39] Risk Considerations - Potential risks include unexpected macroeconomic policies, global liquidity fluctuations, and geopolitical tensions, which could impact market stability[1][4]

医药生物 行 业 研 究 2026 年 02 月 01 日 投资评级：看好（维持） 行业走势图 数据来源：聚源 -10% 0% 10% 19% 29% 38% 2025-02 2025-06 2025-10 医药生物 沪深300 相关研究报告 《原料药行业价格更新—行业周报》 -2026.1.25 《业绩为王，继续重点推荐创新药产 业链板块性机会 — 行 业 周 报 》 -2026.1.18 | 余汝意（分析师） | 刘艺（联系人） | | --- | --- | | yuruyi@kysec.cn | liuyi1@kysec.cn | | 证书编号：S0790523070002 | 证书编号：S0790124070022 | liuyi1@kysec.cn 证书编号：S0790124070022 中国临床 CRO 行业进入"复苏+稳健增长"新阶段，供需结构持续改善 中国创新药产业已完成从十年前的"离岸外包服务模式"到如今"全球创新资产的 贡献者"的跃迁。临床 CRO 行业在经历 2017–2019 年成长期、2020–2022 年高景气 扩张及 2023–2024 年理性回调后，正进入新一轮复苏与稳定增长 ...

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Insights - The report highlights the emergence of HBN, a leading domestic skincare brand, which has submitted its prospectus to the Hong Kong Stock Exchange, indicating strong growth potential in the efficacy skincare market [3][24] - The report emphasizes the importance of emotional consumption themes and suggests focusing on high-quality companies in high-growth sectors [6][49] Summary by Sections Industry Performance Overview - The commercial retail and social services indices reported declines of 4.18% and 3.45% respectively during the week of January 26 to January 30, 2026, ranking 26th and 23rd among 31 primary industries [5][14] - The jewelry sector showed the highest growth, with a weekly increase of 7.07% and a year-to-date increase of 19.39% [15][18] Key Industry Developments - HBN, established in 2019, is recognized as the largest domestic skincare brand in the efficacy skincare segment, with a market share of 0.8% in the Chinese improvement skincare market as of 2024 [24][25] - HBN's revenue for the first three quarters of 2025 reached 1.51 billion yuan, a year-on-year increase of 10.2%, with high-efficacy skincare products accounting for 78.6% of total revenue [29] Investment Recommendations - Investment Theme 1: Focus on high-end gold and fashion jewelry brands, recommending companies like Laopuhuangjin and Chaohongji [6][49] - Investment Theme 2: Highlighting retail companies that adapt to emotional value and intelligent trends, with recommendations for Yonghui Supermarket and Aiyingshi [6][49] - Investment Theme 3: Emphasizing beauty and personal care brands that innovate with emotional value and safe ingredients, recommending brands like Maogeping and Pola [6][50] - Investment Theme 4: Targeting differentiated medical beauty product manufacturers and leading medical beauty institutions, recommending companies like Aimeike and Meilitiantian [6][51]

Group 1 - The current market is in a phase of active thematic investment, with significant opportunities arising from themes such as humanoid robots, commercial aerospace, and AI, which are expected to continue into 2026 [10][11][14] - The report emphasizes the importance of thematic investment during periods of weak fundamentals and ample liquidity, suggesting that such conditions often lead to higher market participation in thematic opportunities [15][20] - Thematic investment thrives on specific catalysts, including technological breakthroughs, policy guidance, and media promotion, which can ignite investor interest and drive market momentum [16][17] Group 2 - The strong performance of the CSI 500 index is attributed to its precise industry allocation that aligns with the cyclical recovery, meeting institutional investment needs and benefiting from liquidity support [26][28] - The CSI 500 index showcases a unique mid-cap growth characteristic, with its average market capitalization at approximately 39.48 billion, allowing it to act as a buffer during market adjustments while also accelerating growth [31][35] - The index's sector distribution is heavily weighted towards manufacturing and technology, which differentiates it from the CSI 300, leading to enhanced resilience during market style shifts [33][37] Group 3 - The report discusses the cyclical recovery and pricing logic, indicating that the PPI's recent improvements signal a potential turning point for industrial prices, which could lead to a broader recovery in cyclical sectors [42][48] - The report highlights that the current market dynamics reflect a transition from external cost-driven price increases to internal demand support, particularly in sectors like chemicals and rebar, which are poised for recovery [48][49]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1][5] Core Insights - The company is expected to achieve a net profit attributable to shareholders of approximately 1.67 to 1.85 billion yuan for 2025, representing a year-on-year increase of 54% to 71%. The adjusted net profit is projected to be between 1.62 to 1.79 billion yuan, reflecting a growth of 53% to 69% year-on-year. However, for Q4 2025, the net profit is anticipated to decline by 202% to 45% due to increased income tax and exchange losses [5] - The company has adjusted its profit forecast for 2025-2027, now estimating net profits of 1.759 billion, 2.316 billion, and 2.954 billion yuan respectively, with corresponding EPS of 24.42, 32.15, and 41.00 yuan. The current stock price corresponds to P/E ratios of 21.2, 16.1, and 12.6 times for the respective years [5] - The company is optimistic about the growth of its two-wheeled vehicles and the continued expansion of its brand channels, expecting double-digit growth and stable profitability. The introduction of new products and steady channel expansion in 2026 is also anticipated to contribute to growth [5][7] Financial Summary - For 2025, the company expects total revenue of approximately 21.403 billion yuan, a year-on-year increase of 50.8%. The net profit margin is projected to be 8.2% for 2025, with a gross margin of 30.3% [8] - The company forecasts a revenue growth of 36.1% in 2026, reaching 29.132 billion yuan, and a further increase of 27.4% in 2027, targeting 37.117 billion yuan [8] - The company's return on equity (ROE) is expected to be 22.1% in 2025, increasing to 23.5% in 2026 and stabilizing at 23.4% in 2027 [8] Product Performance - In Q4 2025, the two-wheeled vehicle segment is expected to focus on inventory clearance, with an estimated shipment of 410 million units for the year, and 200,000 to 300,000 units in Q4, reflecting a decline due to policy changes and inventory management [6] - The all-terrain vehicle segment is projected to maintain growth in non-US regions, while the lawn mower robots are expected to exceed expectations due to low inventory levels and seasonal demand [6][7] - For 2026, the two-wheeled vehicle segment is anticipated to outperform industry growth, with a target of 30% volume increase, while the lawn mower robots are expected to see revenue growth double year-on-year [7]

医药生物 行 业 研 究 2026 年 02 月 01 日 投资评级：看好（维持） 行业走势图 数据来源：聚源 -10% 0% 10% 19% 29% 38% 2025-02 2025-06 2025-10 医药生物 沪深300 相关研究报告 《原料药行业价格更新—行业周报》 -2026.1.25 《业绩为王，继续重点推荐创新药产 业链板块性机会 — 行 业 周 报 》 -2026.1.18 《减重新靶点初显锋芒，小核酸疗法 前景可期—行业周报》-2026.1.11 供需双改善，国内临床 CRO 行业进入发展新阶段 ——行业周报 | 余汝意（分析师） | 刘艺（联系人） | | --- | --- | | | liuyi1@kysec.cn | | yuruyi@kysec.cn | | | 证书编号：S0790523070002 | 证书编号：S0790124070022 | liuyi1@kysec.cn 证书编号：S0790124070022 中国临床 CRO 行业进入"复苏+稳健增长"新阶段，供需结构持续改善 中国创新药产业已完成从十年前的"离岸外包服务模式"到如今"全球创新资产的 贡献者"的跃迁。临 ...